SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cambridge Antibody Technology Group
An SI Board Since December 1999
Posts SubjectMarks Bans
625 23 0
Emcee:  Jongmans Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
300<i>results contd.</i> CAMBRIDGE ANTIBODY TECHNOLOGY Gnigel bates-11/18/2002
299<i>results contd.</i> Licensed programmes As well as Humira(TM), dnigel bates-11/18/2002
298RESULTS - MELBOURN, England, Nov. 18 /PRNewswire-FirstCall/ Highlights nigel bates-11/18/2002
297Bit more on the TRAIL MABs from HGSI - Message 18222150nigel bates-11/12/2002
296re yeast display IP (Abbott seems to be the exclusive licensee to the technologynigel bates-11/11/2002
295MELBOURN, England, Oct. 30 /PRNewswire-FirstCall/ -- Cambridge Antibody Technolonigel bates-10/30/2002
294The phrase deals with "without a license". Also Xoma has already stataknahow-10/28/2002
293It's a little ambiguous - <i>consequently companies engaging in antibonigel bates-10/28/2002
292Well it is not Morphosys as they signed an agreement back in February, giving thaknahow-10/28/2002
291i think its morphosys and crucell both ve a deal with dyax cheers Sdalroi-10/28/2002
290Not sure why other four "infringers" are kept confidential while CAT iaknahow-10/28/2002
289This has got to set a record for length in a PR. (Amgen just released 2 chest-pkeokalani'nui-10/25/2002
288ABBOTT PARK, Ill., Oct. 9 /PRNewswire-FirstCall/ -- Abbott Laboratories announcenigel bates-10/9/2002
287Cambridge Antibody Technology Partners With Chugai to Develop Novel Human Monoclnigel bates-9/30/2002
286Haven't changed my opinion on the clinical programs since Spring; except thakeokalani'nui-9/24/2002
285Wilder, CAT missed firesale status by a whisker today. Possible to buy it withtuck-9/24/2002
284>>8:33AM Abbott Labs upgraded at Merrill Lynch (ABT) 38.59: Merrill Lynch tuck-9/18/2002
283Colour article on D2E7 - Abbott Sees New Uses For Rheumatoid Arthritis Drug Frnigel bates-9/8/2002
282ABBOTT PARK, Ill., Sept. 4 /PRNewswire-FirstCall/ -- Abbott Laboratories (NYSE: nigel bates-9/4/2002
281<i>Weston Medical...</i> By Ben Hirschler, European Pharmaceuticals nigel bates-9/3/2002
280By Mark Potter LONDON, Aug 28 (Reuters) - Britain's Cambridge Antibody Technnigel bates-8/28/2002
279MELBOURN, England, Aug. 28 /PRNewswire-FirstCall/ -- Cambridge Antibody Technolonigel bates-8/28/2002
278MELBOURN, England, and MARTINSRIED, Germany, Aug. 13 /PRNewswire-FirstCall/ -- Cnigel bates-8/13/2002
277Thanks Nigel. Unfortunately, in this market that's a pretty good explanaJFitnich-7/15/2002
276JF, this might help - uk.finance.yahoo.com Volume has been pretty nugatory in nigel bates-7/15/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News